Objective: To assess the effect of infliximab (IFX) on joint destruction in patients with rheumatoid arthritis (RA) .
Methods: We evaluated changes in X-ray images of the hands and feet of RA patients treated with IFX for at least one year. Twenty-five cases (10 males and 15 females) were evaluated. The mean age and disease duration were 52.2 ± 12.1 (range: 25-66) and 9.6 ± 6.3 (range: 1.7-24) years, respectively. The distributions of Steinbrocker's stage and class were I : 2, II : 10, III: 4, IV: 9 and 1: 10, 2: 10, 3: 4, 4: 2 respectively, and the American College of Rheumatology (ACR) responses were ACR 0×9, ACR 20×5, ACR 50×4, ACR 70×7 at one year. We evaluated the hands of one patient by compact magnetic resonance imagines (cMRI) before and after IFX treatment (6 times, 30 weeks) .
Results: No worsening was observed in 20 cases (80.0%) in the hands and in 22 cases (88.0%) in the feet. After 1.5, 2 and 2.5 years, 7 (63.6%) and 8 (72.7%) cases out of 11, 3 (37.5%) and 5 (62.5%) cases out of 8, and 1 (16.7%) and 4 (66.7%) cases out of 6, respectively, did not exhibit worsening in the hands and feet respectively. Six cases showed worsening after one year, with ACR responses of ACR 0×1, ACR 20×1, ACR 50×3, and ACR 70×1. In the case examined by cMRI, erosions had improved dramatically.
Conclusion: IFX appears to prevent joint destruction to some extent. Joint destruction may not be related to the ACR response, and further analysis using cMRI is required to assess this possibly.
抄録全体を表示